Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Shareholder Meeting (August 2023)
39 slides from Little Green Pharma's shareholder meeting presentation, Aug 29, 2023
Slide 1: The most trusted medicinal cannabis brand
glitle green sus oharma The most trusted medicinal cannabis brand
Slide 2: Disclaimer
Disclaimer Disclaimer SS this presentation contains summary information about Little Green Pharma Ltd (ACN 616 686 216) (‘LGP")andiits = activities current as at the date of this presentation, The information in this presentation is of general background and K doesnot purport tobe complete or to con
Slide 3: For personal use only
For personal use only
Slide 4: Little Green Pharma is Different
For personal use only Little Green Pharma is Different Trusted brand and unique position as a vertically integrated company strategically located across continents Setting new standards of excellence with GMP cannabis production facilities in Australia and Denmark First movers in the industry being
Slide 5: For personal use only
For personal use only
Slide 6: Market Analysis Australia
For personal use only Market Analysis Australia During 2022, an estimated total of 1.7 million units of medicinal cannabis products were dispensed with an estimated retail value of $245m' Consistent with previous trends, the primary reasons for prescribing medicinal cannabis were chronic pain (42%),
Slide 7: Market Analysis Europe
For personal use only Market Analysis | Europe The spotlight in the global medicinal cannabis industry is firmly on Europe, with its potential to become the world's largest market Ata global level, Europe stands out as the leading destination for medical cannabis exports, with a few key markets rely
Slide 8: LGP Denmark: in a league of its own
LGP Denmark: in a league of its own
Slide 9: For personal use only
For personal use only • • • • • • • • • •
Slide 10: For personal use only
For personal use only ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Slide 11: The Industry is Consolidating, LGP has already done it
The Industry is Consolidating, geen LGP has already done it pharma LGP is a multi-national, vertically integrated medicinal cannabis company which means we have complete control across the entire supply chain. While our peers focus on one or two segments of the value chain, LGP covers the field: G3
Slide 12: Growth Strategy
Growth Strategy LGP's core strategy remains unchanged: build sales, leverage manufacturing expertise and capacity to unlock high-value markets and innovate products for short-term gains and long-term growth. With a well-established growth strategy, LGP aims to enhance margins and drive substantial r
Slide 13: For personal use only
For personal use only Millions 1 The graphs in this document are unaudited and reflective of past performance data only. Investors should not consider past performance to be indicative of future performance 2 FY2022 was a 9-month financial period
Slide 14: Industry Comparison
For personal use only Industry Comparison Comparative quarterly cash receipts for medicinal cannabis sales of ASX listed companies over a 12-month period! Quarterly Cash Receipts Millions Jun-22 Sep-22 Deo-22 Mar-23 LGP ECS CAN AGH * MXC ACB ZLD BOD 1. Source for all quarterly cashflow data reported
Slide 15: Our Focus
Our Focus The medicinal cannabis industry is a big market and in its infancy. We want to grow quickly and gain market share. We are fully committed to achieving cash flow breakeven in the near-term as we move closer to becoming profitable.
Slide 16: For personal use only
For personal use only
Slide 17: Approaching Cashflow Breakeven
For personal use only Approaching Cashflow Breakeven Our attention is firmly on achieving cashflow breakeven as we move towards profitability Quarterly cashflow from operations since its listing in February 2020 ($m)!2 0 enEngpaeeng ed ed Q3FY20, & QURK20= = OIFY2I~ — Q2FeIT = QGFY2I Q4FY21 QIFY22 Q
Slide 18: Pathway to Profitability
Pathway to Profitability _>Amidst casualties and consolidations in the competitive < medicinal cannabis industry worldwide, there are © rewards for those who survive. The prize will belong to © companies capable of meeting the ongoing demand for W high-quality products at reasonable prices LGP will
Slide 19: Danish Facility
For personal use only DANISH FACILITY
Slide 20: Analyst quote on EU medical market
“We believe the EU medical market has great potential. Recent updates in the EU out of Germany and the Czech Republic suggest to us we could be reaching a critical inflection point for the EU cannabis market, and potentially on the cusp of seeing meaningful acceleration and change over the next coup
Slide 21: For personal use only
For personal use only • • • • • • • •
Slide 22: For personal use only
For personal use only • • • • • • • •
Slide 23: For personal use only
For personal use only • • • • • • • •
Slide 24: For personal use only
For personal use only • • • • • • • • • •
Slide 25: For personal use only
For personal use only
Slide 26: R&I Overview: Product Expansion & Clinical Validation
For personal use only R&l Overview: Product Expansion & Clinical Validation Solving real patient problems — now and in the future 5 . Current Product Offering 6 x extract oils; 7 x flower medicines; 3 x cartridge range for oil vaporisation Meeting-Market- g Demand . _ Launching Soon THC 50 Indica Oi
Slide 27: R&I Overview: Innovation & Drug Registration Strategy
For personal use only R&l Overview: Innovation & Drug Registration Strategy Solving real patient problems - now and in the future Lead-the-Market Strategy Clinical indications - drug registration (TGA/EMA) Lead-the-Market Strategy Drug development Schedule 3 - Over the Counter Drug Registration (Aus
Slide 28: Differentiating Australian & North American Cannabis Markets
Differentiating North American Australian & \ Cannabis Markets . For personal .
Slide 29: Distinct Investment Landscape
For personal use only Distinct Investment Landscape Differentiating Australian & North American Cannabis Companies The US and Canada impose heavy taxes threatening companies: In the US, the 280e tax code prohibits businesses engaged in the sale of cannabis from deducting normal business expenses ess
Slide 30: Market Opportunity
For personal use only Market Opportunity Fuelled by the wave of legalisation initiatives sweeping across the US, both the medical and recreational cannabis markets are expected to sustain robust growth for the foreseeable future In recent years, sales of legal cannabis have already surpassed those o
Slide 31: For personal use only
For personal use only
Slide 32: Awards
For personal use only 2023 WINNER 2023 WINNER 2023 WINNER 2022 WINNER 2022 WINNER 2022 FINALIST
Slide 33: LGP solves societal and environmental challenges
LGP solves societal and environmental challenges through core business activities through six dimensions For personal use only
Slide 34: Meet the Team
For personal use only Meet the Team The Board of Directors The Executive Team The Management Team
Slide 35: Corporate Overview
For personal use only Corporate Overview Capital Structure Current Share Price’ $0.17 Shares Outstanding! ~300 million Options and Performance Rights on Issue” ~39 million Market Capitalisation (undiluted) ~$51 million Cash Reserves (30 June 2023) $8.7 million Enterprise Value (30 June 2023) ~$50 mi
Slide 36: A global leader in medicinal cannabis and psychedelics
ly = A global leader in medicinal cannabis —e and psychedelics ¢ Weare a multi-national GMP cannabis manufacturer with world-class facilities in Denmark and Australia ¢ Our broad distribution network spans multiple EU jurisdictions, making us a highly diversified supplier personal use on e« We condu
Slide 37: For personal use only
zures. Under the leadership of CEO Fleta Solomon, LGP expanded its mission to provide medicinal cannabis products to all Australian patients and export Australian medicinal cannabis to Europe. The company has grown rapidly, becoming publicly listed on the ASX and expanding its operations globally. W
Slide 38: For personal use only
For personal use only
Slide 39: For personal use only
For personal use only
Little Green Pharma — Shareholder Meeting (August 2023) on 6ix